Publication:
Health economic evaluation of Gd-EOB-DTPA MRI vs ECCM-MRI and multi-detector computed tomography in patients with suspected hepatocellular carcinoma in Thailand and South Korea

dc.contributor.authorJeong Min Leeen_US
dc.contributor.authorMyeong Jin Kimen_US
dc.contributor.authorSith Phongkitkarunen_US
dc.contributor.authorAbhasnee Sobhonslidsuken_US
dc.contributor.authorAnke Peggy Holtorfen_US
dc.contributor.authorHarald Rindeen_US
dc.contributor.authorKarsten Bergmannen_US
dc.contributor.otherSeoul National University College of Medicineen_US
dc.contributor.otherSeverance Hospitalen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherHealth Outcomes Strategiesen_US
dc.contributor.otherBayer Pharma AGen_US
dc.date.accessioned2018-12-11T03:31:25Z
dc.date.accessioned2019-03-14T08:02:10Z
dc.date.available2018-12-11T03:31:25Z
dc.date.available2019-03-14T08:02:10Z
dc.date.issued2016-08-02en_US
dc.description.abstract© 2016 Informa UK Limited, trading as Taylor & Francis Group. Abstract: Objective: The effectiveness of treatment decisions and economic outcomes of using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-MRI) were compared with extracellular contrast media-enhanced MRI (ECCM-MRI) and multi-detector computed tomography (MDCT) as initial procedures in patients with suspected hepatocellular carcinoma (HCC) in South Korea and Thailand. Methods: A decision-tree model simulated the clinical pathway for patients with suspected HCC from the first imaging procedure to a confirmed treatment decision. Input data (probabilities and resource consumptions) were estimated and validated by clinical experts. Costs for diagnostic alternatives and related treatment options were derived from published sources, taking into account both payer’s and hospital’s perspectives. Results: All experts from Korea and Thailand agreed that Gd-EOB-DTPA-MRI yields the highest diagnostic certainty and minimizes the need for additional confirmatory diagnostic procedures in HCC. In Korea, from the payer’s perspective, total cost was USD $3087/patient to reach a confirmed treatment decision using Gd-EOB-DTPA-MRI (vs $3205/patient for MDCT and $3403/patient for ECCM-MRI). From the hospital’s perspective, Gd-EOB-DTPA-MRI incurred the lowest cost ($2289/patient vs $2320/patient and $2528/patient, respectively). In Thailand, Gd-EOB-DTPA-MRI was the least costly alternative for the payer ($702/patient vs $931/patient for MDCT and $873/patient for ECCM-MRI). From the hospital’s perspective, costs were $1106/patient, $1178/patient, and $1087/patient for Gd-EOB-DTPA-MRI, MDCT, and ECCM-MRI, respectively. Conclusions: Gd-EOB-DTPA-MRI as an initial imaging procedure in patients with suspected HCC provides better diagnostic certainty and relevant statutory health insurance cost savings in Thailand and Korea, compared with ECCM-MRI and MDCT.en_US
dc.identifier.citationJournal of Medical Economics. Vol.19, No.8 (2016), 759-768en_US
dc.identifier.doi10.3111/13696998.2016.1171230en_US
dc.identifier.issn1941837Xen_US
dc.identifier.issn13696998en_US
dc.identifier.other2-s2.0-84978395249en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/41241
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84978395249&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleHealth economic evaluation of Gd-EOB-DTPA MRI vs ECCM-MRI and multi-detector computed tomography in patients with suspected hepatocellular carcinoma in Thailand and South Koreaen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84978395249&origin=inwarden_US

Files

Collections